Last 7 days
-22.3%
Last 30 days
-33.8%
Last 90 days
-53.1%
Trailing 12 Months
-48.7%
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 80.6% | 1,351 | 748 | 307 | 94.00 | 69.00 |
Operating Expenses | 13.1% | 42,262 | 37,380 | 32,542 | 27,207 | 21,574 |
S&GA Expenses | 18.0% | 12,751 | 10,809 | 9,054 | 6,317 | 4,668 |
R&D Expenses | 13.7% | 28,511 | 25,071 | 22,988 | 20,140 | 16,156 |
Net Income | -11.7% | -40,956 | -36,659 | -32,263 | -27,150 | -21,543 |
Net Income Margin | 54.3% | -40.38* | -88.28* | -301.48* | -415* | - |
Free Cahsflow | -22.8% | -34,432 | -28,037 | -23,998 | -13,600 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -6.8% | 103 | 110 | 120 | 121 | 65.00 |
Current Assets | -8.1% | 99.00 | 107 | 117 | 120 | 60.00 |
Cash Equivalents | -5.5% | 27.00 | 29.00 | 41.00 | 83.00 | 12.00 |
Liabilities | 62.1% | 7.00 | 4.00 | 4.00 | 5.00 | 3.00 |
Current Liabilities | 62.1% | 7.00 | 4.00 | 4.00 | 5.00 | 3.00 |
Shareholder's Equity | -9.7% | 95.00 | 106 | 116 | 115 | -47.41 |
Retained Earnings | -15.2% | -89.72 | -77.88 | -66.54 | -56.42 | -47.38 |
Additional Paid-In Capital | 0.8% | 185 | 184 | 183 | 172 | - |
Shares Outstanding | 0% | 19.00 | 19.00 | 19.00 | 19.00 | 3.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 3.9% | -33.46 | -34.82 | -30.02 | -25.68 | -20.48 |
Share Based Compensation | 31.0% | 4.00 | 3.00 | 2.00 | 1.00 | 1.00 |
Cashflow From Investing | -0.9% | -21.77 | -21.58 | -26.25 | 18.00 | -50.02 |
Cashflow From Financing | 1.4% | 70.00 | 69.00 | 69.00 | 62.00 | 79.00 |
85.7%
85.7%
85.7%
Y-axis is the maximum loss one would have experienced if AN2 Therapeutics was unfortunately bought at previous high price.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-22 | American Trust | added | 3.27 | -34,953 | 435,440 | 0.03% |
2023-05-22 | Arete Wealth Advisors, LLC | added | 0.14 | -375,148,000 | 337,000 | 0.03% |
2023-05-22 | Raleigh Capital Management Inc. | added | 313 | 198,680 | 272,190 | 0.14% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 12.92 | 18,688,300 | 1,664,420,000 | 0.55% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 1,655,000 | 0.07% |
2023-05-22 | PUTNAM INVESTMENTS LLC | added | 2.62 | -37,329,300 | 428,357,000 | 0.69% |
2023-05-19 | Trivant Custom Portfolio Group, LLC | new | - | 2,989,680 | 2,989,680 | 2.14% |
2023-05-19 | Coppell Advisory Solutions LLC | sold off | -100 | -11,798 | - | -% |
2023-05-18 | COURIER CAPITAL LLC | added | 3.57 | -20,573 | 266,690 | 0.03% |
2023-05-18 | JPMORGAN CHASE & CO | added | 35.87 | 24,000 | 84,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | ra capital management, l.p. | 19.5% | 3,773,517 | SC 13G/A | |
Feb 14, 2023 | citadel advisors llc | 6.9% | 6 | SC 13G/A | |
Feb 14, 2023 | biotechnology value fund l p | 4.4% | 846,993 | SC 13G/A | |
Feb 13, 2023 | pfizer inc | 7.02% | 0 | SC 13G | |
Feb 13, 2023 | brii biosciences ltd | 5.4% | 1,048,479 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
May 15, 2023 | 4 | Insider Trading | |
May 11, 2023 | 10-Q | Quarterly Report | |
May 11, 2023 | 8-K | Current Report | |
Apr 26, 2023 | ARS | ARS | |
Apr 26, 2023 | DEF 14A | DEF 14A | |
Apr 26, 2023 | DEFA14A | DEFA14A | |
Apr 14, 2023 | 424B5 | Prospectus Filed | |
Apr 13, 2023 | EFFECT | EFFECT | |
Apr 11, 2023 | CORRESP | CORRESP | |
Apr 10, 2023 | UPLOAD | UPLOAD |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-15 | Easom Eric | bought | 53,770 | 5.377 | 10,000 | chief executive officer |
2022-11-14 | Easom Eric | sold | -345 | 15.04 | -23.00 | chief executive officer |
2022-11-10 | Easom Eric | sold | -67,628 | 15.3248 | -4,413 | chief executive officer |
2022-11-09 | Easom Eric | sold | -157,847 | 15.6114 | -10,111 | chief executive officer |
2022-11-08 | Easom Eric | sold | -109,947 | 15.5842 | -7,055 | chief executive officer |
2022-11-07 | Easom Eric | sold | -195,741 | 16.0404 | -12,203 | chief executive officer |
2022-11-04 | Easom Eric | sold | -139,474 | 15.7991 | -8,828 | chief executive officer |
2022-11-03 | Easom Eric | sold | -223,058 | 15.7472 | -14,165 | chief executive officer |
2022-11-02 | Easom Eric | sold | -23,262 | 15.0664 | -1,544 | chief executive officer |
2022-10-31 | Easom Eric | sold | -41,362 | 15.3879 | -2,688 | chief executive officer |
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating expenses: | ||
Research and development expense related party | $ 11,985 | $ 5,633 |
General and administrative | 4,054 | 2,050 |
Total operating expenses | 16,039 | 7,683 |
Loss from operations | (16,039) | (7,683) |
Other income, net | 716 | 28 |
Net loss | (15,323) | (7,655) |
Accretion to redemption value and cumulative dividends on preferred stock | (1,820) | |
Net loss attributable to common stockholders | $ (15,323) | $ (9,475) |
Net loss per share attributable to common stockholders, basic | $ (0.79) | $ (2.98) |
Net loss per share attributable to common stockholders, diluted | $ (0.79) | $ (2.98) |
Weighted-average number of shares used in computing net loss per share, basic | 19,385,646 | 3,180,717 |
Weighted-average number of shares used in computing net loss per share, diluted | 19,385,646 | 3,180,717 |
Other comprehensive loss: | ||
Unrealized gain (loss) on investments | $ 199 | $ (131) |
Comprehensive loss | $ (15,124) | $ (7,786) |
CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 26,709 | $ 27,219 |
Short-term investments | 61,806 | 68,840 |
Prepaid expenses and other current assets | 1,767 | 2,509 |
Right-of-use asset, net | 34 | 53 |
Total current assets | 90,316 | 98,621 |
Deferred offering costs | 48 | |
Long-term investments | 3,219 | |
Other assets, long-term | 720 | 720 |
Total assets | 91,084 | 102,560 |
Current liabilities: | ||
Accounts payable | 3,545 | 2,122 |
Accrued compensation | 741 | 2,168 |
Accrued liabilities | 4,241 | 2,837 |
Operating lease liabilities | 34 | 53 |
Options subject to repurchase, short-term | 5 | 6 |
Total current liabilities | 8,566 | 7,186 |
Options subject to repurchase, long-term | 1 | 2 |
Total liabilities | 8,567 | 7,188 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity: | ||
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022 | ||
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2023 and December 31, 2022; 19,426,452 and 19,402,658 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | ||
Additional paid-in capital | 187,738 | 185,469 |
Accumulated other comprehensive loss | (175) | (374) |
Accumulated deficit | (105,046) | (89,723) |
Total stockholders' equity | 82,517 | 95,372 |
Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $ 91,084 | $ 102,560 |